Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma - Takeaways - MDSpire

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma

  • By

  • Shuang Xiang

  • Zhuomiao Ye

  • Yifan Dai

  • Shipeng Shang

  • Dan Yang

  • Tao Cheng

  • Chao Deng

  • Minghui Zhang

  • Mingzhu Yin

  • May 28, 2026

  • 0 min

Share

  • 1

    NUT carcinoma is a rare, aggressive malignancy characterized by NUTM1 gene rearrangements, often misclassified in clinical settings.

  • 2

    The study analyzed 229 cases, revealing a predominance of squamous lineage and significant associations between fusion partners and tumor phenotype.

  • 3

    PD-L1 expression was predominantly negative in 76.92% of cases, indicating a generally immunologically 'cold' phenotype in NUT carcinoma.

  • 4

    The research highlighted the need for a systematic framework to connect fusion partners with clinicopathologic features and immune biomarkers.

  • 5

    Findings support the exploration of fusion partner-specific patterns to enhance diagnostic accuracy and guide future biomarker studies.

Original Source(s)

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma

  • by Shuang Xiang, Zhuomiao Ye, Yifan Dai, Shipeng Shang, Dan Yang, Tao Cheng, Chao Deng, Minghui Zhang, Mingzhu Yin

  • May 28, 2026

Related Content

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

MRI perfusion in evaluating ovarian masses: diagnostic performance of wash out rate